

Claims

Please replace originally filed claims with the claims indicated below:

1. (original) δ crystalline form of perindopril erbumine, characterised by the following X-ray diffraction data (measured on a powder diffractometer with CuK_α irradiation):

Angle 2 theta (°)	Lattice spacing d (Å)	Relative intensity I/I _{max} (%)
5.27	16.79	2
8.93	9.93	100
9.75	9.10	32
10.65	8.34	10
14.63	6.10	25
14.97	5.97	39
15.27	5.85	48
15.95	5.61	53
17.27	5.19	18
17.87	5.02	15
18.63	4.83	13

19.99	4.51	29
20.37	4.43	26
21.31	4.24	57
21.83	4.15	37
22.49	4.03	26
23.15	3.92	19
23.65	3.84	29
23.99	3.79	16
24.71	3.69	15
25.33	3.60	15
25.75	3.55	15
26.43	3.46	21
26.77	3.42	18
28.19	3.26	24

2. (cancelled)

3. (cancelled)

4. (previously presented) Medicaments, containing a crystalline form of perindopril erbumine according to claim 1.

5. (previously presented) A solid pharmaceutical composition comprising as active ingredient the compound according to claim 1, in combination with one or more pharmaceutically acceptable, inert, non-toxic carriers.

6. (previously presented) The solid pharmaceutical composition according to claim 5 for use as ACE inhibitor in the treatment of hypertension, stable coronary artery disease, and heart failure.

7. (original) Process for the preparation of perindopril erbumine of the δ crystalline form according to claim 1, characterised in that

a) perindopril erbumine of any crystalline form is recrystallised at from 30 to 45°C from tert-butyl methyl ether containing from 1.5 to 2.5 % (v/v) water, and the precipitate obtained is stirred for at least 15 hours at from 30 to 45°C after the removal of water;

or

b) perindopril erbumine of the α or β crystalline form is stirred at from 33 to 38°C in tert.-butyl methyl ether containing from 0.9 to 1.4 % (v/v) water with seeding with the δ crystalline form.

8. (cancelled)

9. (cancelled)

10. (cancelled)

11. (cancelled)

12. (cancelled)

13. (cancelled)

14. (cancelled)